Sean P. Nolan

CIK: 0001569926

Transaction Breakdown

Open Market Buys (P)4 (40.0%)

High conviction signal

Open Market Sales (S)2 (20.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

VTR

Ventas, Inc.

Director

TSHA

Taysha Gene Therapies, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

VTR
Ventas, Inc.
May 13, 2026
Award(A)
Direct
2K shares at avg. $90.35$185K
TSHA
Taysha Gene Therapies, Inc.
Jan 26, 2026
Sale(S)
Direct
41.3K shares at avg. $4.61$190K
TSHA
Taysha Gene Therapies, Inc.
Jan 23, 2026
Sale(S)
Direct
136.8K shares at avg. $4.75$650K
TSHA
Taysha Gene Therapies, Inc.
Jan 12, 2026
Award(A)
Direct
1M shares-
VTR
Ventas, Inc.
May 13, 2025
Award(A)
Direct
2.9K shares at avg. $64.18$185K
TSHA
Taysha Gene Therapies, Inc.
Jan 2, 2025
Award(A)
Direct
892.5K shares-
VTR
Ventas, Inc.
Jul 21, 2020
Purchase(P)
Indirect
37 shares at avg. $34.21$1K
VTR
Ventas, Inc.
Jul 21, 2020
Purchase(P)
Indirect
27 shares at avg. $34.21$923.781
VTR
Ventas, Inc.
Apr 20, 2020
Purchase(P)
Indirect
36 shares at avg. $27.70$997.07
VTR
Ventas, Inc.
Apr 20, 2020
Purchase(P)
Indirect
50 shares at avg. $27.70$1K

		Type	Shares	Price		Ownership
May 13, 2026	VTR Ventas, Inc.	Award(A)	2,047	$90.35	$184,946	Direct
Jan 26, 2026	TSHA Taysha Gene Therapies, Inc.	Sale(S)	41,312	$4.61	$190,448	Direct
Jan 23, 2026	TSHA Taysha Gene Therapies, Inc.	Sale(S)	136,789	$4.75	$649,748	Direct
Jan 12, 2026	TSHA Taysha Gene Therapies, Inc.	Award(A)	1,008,000	-	$0	Direct
May 13, 2025	VTR Ventas, Inc.	Award(A)	2,882	$64.18	$184,967	Direct
Jan 2, 2025	TSHA Taysha Gene Therapies, Inc.	Award(A)	892,500	-	$0	Direct
Jul 21, 2020	VTR Ventas, Inc.	Purchase(P)	37	$34.21	$1,266	Indirect
Jul 21, 2020	VTR Ventas, Inc.	Purchase(P)	27	$34.21	$924	Indirect
Apr 20, 2020	VTR Ventas, Inc.	Purchase(P)	36	$27.70	$997	Indirect
Apr 20, 2020	VTR Ventas, Inc.	Purchase(P)	50	$27.70	$1,385	Indirect

1-10 of 10 transactions

About Nolan Sean P.

Nolan Sean P. (SEC CIK 0001569926) files insider reports with the SEC as Director of Ventas, Inc. (VTR) and Chief Executive Officer of Taysha Gene Therapies, Inc. (TSHA).

Signal8 holds 6 ownership filings by Nolan Sean P. (5 Form 4, 1 Form 5), filed between Jan 3, 2025 and May 15, 2026. Those filings report 10 transactions, from Apr 20, 2020 to May 13, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Nolan Sean P.'s filings is in CHICAGO, IL.

Recent filings by Nolan Sean P.

May 13, 2026: Grant or award of VTR shares (Form 4, code A).
Jan 26, 2026: Open-market sale of TSHA shares (Form 4, code S).
Jan 23, 2026: Open-market sale of TSHA shares (Form 4, code S).
Jan 12, 2026: Grant or award of TSHA shares (Form 4, code A).
May 13, 2025: Grant or award of VTR shares (Form 4, code A).

Other insiders filing for Ventas, Inc. (VTR)

How to read Form 4 transaction codes